Chinese Journal of Pharmacovigilance ›› 2024, Vol. 21 ›› Issue (2): 141-146.
DOI: 10.19803/j.1672-8629.20230411
Previous Articles Next Articles
JIA Yinyin1,2, ZHANG Caishu2, ZHOU Ying2, LIU Li3, GENG Ying2, WEI Ningyi2, NIU Sijing2, CHEN Hua2,*, XU Hui1#
Received:
2023-06-28
Online:
2024-02-15
Published:
2024-02-06
CLC Number:
JIA Yinyin, ZHANG Caishu, ZHOU Ying, LIU Li, GENG Ying, WEI Ningyi, NIU Sijing, CHEN Hua, XU Hui. Evaluation methods for aerodynamic particle size distribution of fine particles in inhaled products[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 141-146.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgywjj.com/EN/10.19803/j.1672-8629.20230411
[1] SENG HL, PAPK S, LEE CC, et al.A 3D printed human upper respiratory tract model for particulate deposition profiling[J]. Int J Pharm, 2021, 597: 120307. [2] SORINO C, NEGRI S, SPANEVELLO A, et al.Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler[J]. Eur J Intern Med, 2020, 75: 15-18. [3] ROBERTS DL, MITCHELL JP.Measurement of aerodynamic particle size distribution of orally inhaled products by cascade impactor: how to let the product specification drive the quality requirements of the cascade impactor[J]. AAPS PharmSciTech, 2019, 20(2): 57. [4] Chinese Pharmacopoeia Commission.Pharmacopoeia of the People’s Republic of China, Volume IV(中华人民共和国药典四部)[M]. Beijing: China Medical Science Press, 2020: 12-16. [5] European Commission. European Pharmacopoeia.10th edition. Chapter 2.9.18. Preparations for Inhalation[S]. Strasbourg: Council of Europe Strasbourg, 2019: 927-932. [6] United States Pharmacopeial Convention. USP 42-NF 37 Chapter 601: Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders-Performance Quality Tests[S]. Rockville: MD, 2018: 6327-6352. [7] ZHU DF, SHI M, HONG YW, et al.Determination of bromohexine hydrochloride atomized aerosol concentration and aerodynamic particle size distribution analysis[J]. Chinese Journal of Pharmacy(中国药学杂志), 2022, 57(21): 1834-1841. [8] DOUB W, STEIN S, MITCHELL J, et al.Addressing the need for controls on particle bounce and re-entrainment in the cascade impactor and for the mitigation of electrostatic charge for aerodynamic particle size assessment of orally inhaled products: an assessment by the international consortium on regulation and science (IPAC-RS)[J]. AAPS PharmSciTech, 2020, 21(7): 239. [9] CHEN LY, ZHANG CF, LI YF, et al.Research progress on the evaluation of aerodynamic particle size distribution of inhalation preparations by impactor method[J]. Drug Evaluation studies(药物评价研究), 2019, 42(12): 2332-2336. [10] NEWMAN SP, CHAN HK. [11] WANG XY, GAO L, ZHOU Y, et al.Three impactors determined the aerodynamic particle size distribution of salmeterolticasone inhaled powder aerosol[J]. Journal of Pharmaceutical Analysis(药物分析杂志), 2020, 40(1): 186-197. [12] ROBERTS DL, CHAMBERS F, COPLEY M, et al.Internal volumes of pharmaceutical compendial induction port, next-generation impactor with and without its pre-separator, and several configurations of the andersen cascade impactor with and without pre-separator[J]. J Aerosol Med Pulm Drug Deliv, 2020, 33(4): 214-229. [13] PRICE R, SHUR J, GANLEY W, et al.Development of an aerosol dose collection apparatus for in vitro dissolution measurements of orally inhaled drug products[J]. AAPS J, 2020, 22(2): 47. [14] MITCHELL JP, STEIN SW, DOUB W, et al.Determination of passive dry powder inhaler aerodynamic particle size distribution by multi-stage cascade impactor: international pharmaceutical aerosol consortium on regulation & science (IPAC-RS) recommendations to support both product quality control and clinical programs[J]. AAPS PharmSciTech, 2019, 20(5): 206. [15] European Commission. European Pharmacopoeia (9th edition). Chapter 2.9.44. Preparations for nebulization: characterization[S]. Strasbourg: Council of Europe Strasbourg, 2017: 378-381. [16] European Commission. European Pharmacopoeia (9th edition). Chapter 2.9.18. Preparations for inhalation: aerodynamic assessment of fine particles[S]. Strasbourg: Council of Europe Strasbourg, 2017: 323-335. [17] TOUGAS TP, MITCHELL JP, LYAPUSTINA SA.Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products[M]. Boston MA: Springer US, 2013: 95-102. [18] TOUGAS TP, MITCHELL JP, LYAPUSTINA SA.Good Cascade Impactor Practices, AIM and EDA for Orally Inhaled Products[M]. Boston MA: Springer US, 2013: 114-117. [19] CHRISTOPHER J D, DEY M, LYAPUSTINA S, et al.Generalized simplified approaches for mass median aerodynamic determination[J]. Pharmacopeial Forum, 2010, 36(3): 812-823. [20] WANG Z, WEI NY, ZHOU Y, et al.Comparison of atomization characteristics of inhalation solution of ambroxol hydrochloride with different prescriptions[J]. Chinese Journal of New Drugs(中国新药杂志), 2020, 29(13): 1535-1539. [21] TOUGAS TP, GOODEY AP, HARDWELL G, et al.A comparison of the performance of efficient data analysis versus fine particle dose as metrics for the quality control of aerodynamic particle size distributions of orally inhaled pharmaceuticals[J]. AAPS PharmSciTech, 2017, 18(2): 451-461. [22] ZHAO YL, RACO J, KOURMATZIS A, et al.The effects of upper airway tissue motion on airflow dynamics[J]. J Biomech, 2020, 99: 109506. [23] MITCHELL J, NEWMAN S, CHAN H. [24] MITCHELL J, TOUGAS T, LYAPUSTINA S.The abbreviated impactor measurement (AIM) and effective data analysis (EDA) concepts: Why they are important and how to go about working with them[J]. Inhalation Magazine, 2012, 6: 13-19. [25] MOHAN M, LEE S, GUO CN, et al.Evaluation of abbreviated impactor measurements (AIM) and efficient data analysis (EDA) for dry powder inhalers (DPIs) against the full-resolution next generation impactor(NGI)[J]. AAPS PharmSciTech, 2017, 18(5): 1585-1594. [26] MITCHELL JP.Particle size measurements from orally inhaled and nasal drug products[J]. J Aerosol Med Pulm Drug Deliv, 2021, 34(6): 325-345. [27] National Medical Products Administration. Technical guidelines for quality control studies of inhaled formulations (吸入制剂质量控制研究技术指导原则) [EB/OL]. (2007-10-23)[2023-08-27]. https://www.nmpa.gov.cn/wwwroot/gsjz07643/f1.rar. [28] Health Canada. Guidance for industry on the pharmaceutical quality of inhaled and nasal products[EB/OL]. (2006-04-13)[2023-03-07]. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/hpfb-dgpsa/pdf/prodpharma/inhalationnas-eng.pdf. [29] European Medicines Agency. Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products[EB/OL]. (2006-06-21)[2023-03-07]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-quality-inhalation-nasal-products_en.pdf. [30] FDA. Draft Guidance for Industry on Metered Dose Inhaler (MDI) andDry Powder Inhaler (DPI) Drug Products; Chemistry Manufacturing, and Controls Documentation[EB/OL]. (1998-11-19) [2023-03-07]. https://www.govinfo.gov/content/pkg/FR-1998-11-19/pdf/FR-1998-11-19.pdf. [31] FDA. Guidance for Industry: Nasal Spray and Inhalation Solution, Suspension,Spray Drug Products-Chemistry, Manufacturing and Controls Documentation[EB/OL]. (2018-04)[2023-03-07] https://www.fda.gov/media/70857/download. [32] FDA. Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Products - Quality Considerations.Guidance for Industry[EB/OL]. [2023-03-07].https://www.fda.gov/media/70851/download. [33] LEE SL, SALUJA B, GARCIA-ARIETA A, et al.Regulatory considerations for approval of generic inhalation drug products in the US, EU, Brazil, China, and India[J]. AAPS J, 2015, 17(5): 1285-1304. [34] FROEHLICH E.Biological obstacles for identifying [35] SANDELL D.Bioequivalence assessment of pharmaceutical aerosol products through IVIVC[J]. Adv Drug Deliv Rev, 2021, 176: 113895. [36] GENG Y, YANG Q, ZHANG J.Statistical evaluation method of [37] FDA. Statistical Comparison of Particle Size Distribution Profiles[EB/OL]. (2004-09-28)[2023-03-07]. https://pqri.org/wp-content/uploads/2015/08/pdf/DC01-475116-v2-Yi_Tsong_Statistical_Archive_PQRI_Profile_Comparisons.DOC. [38] ADAMS W, CHRISTOPHER D, LEE DS, et al.Product quality research institute evaluation of cascade impactor profiles of pharmaceutical aerosols, part 1: background for a statistical method[J]. AAPS PharmSciTech, 2007, 8(1): 4. [39] CHOW SC, LIU JP.Design and Analysis of Bioavailability and Bioequivalence Studies[M]. Newyork: Wiley, International Statistical Institute (ISI), 2009: 455-459. [40] CHEN LY, XU JN, YANG M, et al.Discussion on population bioequivalence for inhalation preparations[J]. Tianjin Pharmacy(天津药学), 2021, 33(4): 21-24. [41] GAO YD, JIANG WM, LE J.Comparison of physicochemical properties and spray properties of suspension in three nasal sprays[J]. Chinese Journal of New Drugs(中国新药杂志), 2022, 31(16): 1631-1637. [42] SHRESTHA K, VAN STRIEN J, SINGH N, et al.Primary break-up and atomization characteristics of a nasal spray[J]. Plos One, 2020, 15(8): e0236063. [43] GRMAS J, LUZAR-STIFFLER V, DREU R, et al.A novel simulation-based approach for comparing the population against average bioequivalence statistical test for the evaluation of nasal spray products on spray pattern and droplet size distribution parameters[J]. AAPS PharmSciTech, 2019, 20(1): 38. [44] FDA. Guidance for Industry, Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action[EB/OL].[2023-03-07].https://www.fda.gov/media/70867/download. |
[1] | YANG Bo, WANG Mengjiao, HU Lili, WANG Laicheng, LI Qian, KONG Feifei, LYU Dongmei, SHEN Jiani. Safety assessment and risk factor analysis of PD-1 immunotherapy in a cohort of 385 patients [J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 447-450. |
[2] | GU Xiaotong, SUN Xuelin, ZHENG Li. Pharmacological effect and clinical evaluation of rezafungin in treating candidemia and invasive candidiasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 469-472. |
[3] | ZHANG Chenxue, PEI Yusheng, CAI Tong. Research progress in bacterial endotoxin test methods for insoluble raw materials, excipients and preparations [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 273-279. |
[4] | LIU Yi, QIN Ling, GUO Xianhui, CHEN Hua, PEI Yusheng. Applications of TGA and DSC in pharmaceutical analysis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 283-289. |
[5] | ZHANG Xiaoming, LYU Ping, HU Xinyue, DING Xiaoli, LI Jing, LIANG Chenggang. Detection of single-chain precursor residues in insulin glargine by ELISA [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 290-294. |
[6] | LIU Qi, ZHANG Yufeng, LUO Hao, LI Xin. Analysis of the rationality and safety of clinical application of anrotinib in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 329-334. |
[7] | MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172. |
[8] | ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189. |
[9] | GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5. |
[10] | BAI Zhaofang, ZHAN Xiaoyan, YAO Qing, CHEN Simin, ZHAO Xu, XIAO Xiaohe. Theoretical innovation and technological breakthroughs in the safety evaluation of traditional Chinese medicine: disease-syndrome-based toxicology [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 6-14. |
[11] | FANG Zhie, LI Chengxian, BAI Zhaofang, ZHAO Xu, WANG Jiabo, XIAO Xiaohe. Investigation of objectivity in the relationship between aristolochic acid and hepatocellular carcinoma [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 20-24. |
[12] | XIONG Weiyi, REN Jingtian. Considerations for revision of safety information in package inserts of anti-cancer drugs in post-market phase [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 94-97. |
[13] | LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101. |
[14] | CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110. |
[15] | LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||